Quadrant Capital Group LLC Apellis Pharmaceuticals, Inc. Transaction History
Quadrant Capital Group LLC
- $1.43 Billion
- Q4 2024
A detailed history of Quadrant Capital Group LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 261 shares of APLS stock, worth $6,786. This represents 0.0% of its overall portfolio holdings.
Number of Shares
261
Previous 39
569.23%
Holding current value
$6,786
Previous $1,000
700.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding APLS
# of Institutions
302Shares Held
123MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$318 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$309 Million17.73% of portfolio
-
Wellington Management Group LLP Boston, MA11.8MShares$307 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$261 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$250 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.86B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...